National Health Act 1953 - Declaration under subsection 85 (2AA) (No. PB 18 of 1994)

Overview

The National Health Act 1953 was enacted by the Australian Parliament to establish a framework for the provision of health services and the administration of health-related programs across the nation. One of the key components of this Act is the regulation of pharmaceutical benefits, ensuring that Australians have access to affordable and necessary medications. The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the Act, made by the Assistant Secretary of the Pharmaceutical Benefits Branch, Department of Human Services and Health, is a legislative instrument that serves to update and refine the list of pharmaceutical products covered under the Act. This particular declaration, effective from 1 December 1994, was introduced to address the need for regular updates to the Pharmaceutical Benefits Scheme to ensure that it remains current with medical advancements and public health needs. The policy objective of this declaration is to maintain an efficient and effective pharmaceutical benefits system that provides Australians with access to essential medicines while also ensuring the sustainability and fiscal responsibility of the scheme.

Scope and Application

The National Health Act 1953 applies to the regulation of pharmaceutical benefits within Australia, and this particular legislative instrument pertains to the exclusion of certain drugs and medicinal preparations from the scope of Part VII of the Act. The Act applies to persons and entities involved in the provision, supply, or administration of these pharmaceutical benefits, as well as to the entities responsible for the administration of the Pharmaceutical Benefits Scheme (PBS). The geographical reach of this legislation is nationwide, as it is a Commonwealth Act and thus applies across the entire country. The Declaration specifies that the listed drugs and preparations will cease to be covered under the PBS from the date of operation, 1 December 1994. This legislative instrument extends the application of the Act by removing certain drugs from the scope of the Pharmaceutical Benefits, thereby indirectly affecting the industries and individuals involved in the supply, prescription, or administration of those drugs. There are no exclusions, exemptions, or thresholds stated within this particular Declaration, but the broader Act may contain provisions that could affect eligibility or conditions for inclusion or exclusion from the PBS.

Key Provisions

The main operative sections of this Declaration, made under subsection 85 (2AA) of the National Health Act 1953, are detailed in the document itself. Section 1 specifies that the Declaration will come into effect on 1 December 1994. Section 2, the most critical section, states that the drugs and medicinal preparations listed in the Schedule will cease to be covered under Part VII of the National Health Act 1953, which pertains to the Pharmaceutical Benefits Scheme (PBS). This means that from the effective date, the listed medications will no longer be subject to the PBS and will not receive the same level of subsidy or coverage as other pharmaceutical products. The obligations and requirements imposed by this Act are primarily administrative and procedural. The Assistant Secretary, Pharmaceutical Benefits Branch, Department of Human Services and Health, in their role as a delegate of the Minister for Human Services and Health, must follow specific steps to ensure the proper implementation of the Declaration. This includes obtaining the advice of the Pharmaceutical Benefits Advisory Committee as required by subsection 85 (2AB) of the National Health Act 1953. The declaration process ensures that any changes to the list of covered pharmaceutical products are considered and advised upon by relevant experts, ensuring that the decision to remove these medications from the PBS is informed and justifiable. While the National Health Act 1953 itself does not specify particular offences, penalties, or consequences for the breach of this Declaration, general legal principles apply. The Act’s provisions are designed to regulate the PBS, and any failure to comply with the declared changes could result in civil or administrative actions. For example, entities or individuals who continue to claim benefits for the medications listed in the Schedule post-1 December 1994 could face penalties for non-compliance. The exact nature of these penalties would depend on the specific circumstances and relevant legislative provisions governing the PBS. However, breaches could potentially lead to fines or other enforcement actions under the National Health Act 1953 or other related legislation.